Organization
Oncology Research and Development, Pfizer, La Jolla, CA
1 abstract
Abstract
Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.Org: Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada, Moores Cancer Center, University of California San Diego, La Jolla, CA, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Department of Medical Oncology, Baylor Scott and White Health, Dallas, TX,